Peptide · Fact sheet
GHRP-2
Also known as growth hormone-releasing peptide-2 · pralmorelin
GHRP-2 is an experimental growth-hormone secretagogue that activates the ghrelin receptor. It is not FDA approved, and small human physiology studies do not prove that it builds muscle, improves recovery, or slows aging.
What is GHRP-2?
GHRP-2 is a synthetic six-amino-acid peptide that activates the growth-hormone secretagogue receptor, also called the ghrelin receptor.
It can increase growth-hormone release and appetite, but a hormone spike is a biomarker—not a demonstrated body-composition or performance outcome.
Benefits people look for
It is promoted online for muscle growth, recovery, fat loss, sleep, and anti-aging, sometimes alongside other growth-hormone-pathway peptides.
Human studies more clearly show appetite and hormone effects than the desired performance outcomes used in marketing.
What the evidence supports
- Small controlled studies show increased growth hormone and short-term food intake.
- Those biological effects do not demonstrate improved muscle mass, strength, recovery, or healthspan.
All research areas
- Growth-hormone release
- Appetite and food intake
- Endocrine testing and physiology
- Critical-illness metabolism in older research
- Growth-hormone and ghrelin-receptor physiology
- Appetite and metabolic research
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- FDA identifies potential immune reactions, aggregation, peptide impurities, and complexity from an unnatural amino acid.
- FDA notes reports of increased insulin requirements, infection, pancreatitis, and deaths in critically ill study participants, while stating that causality was not established.
- The peptide can increase appetite and may affect glucose and endocrine signaling in ways that conflict with popular body-composition claims.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceSmall controlled human studies establish short-term effects on growth hormone and food intake. They do not establish meaningful muscle growth, recovery, fat loss, sleep, or longevity benefits.
Selected research to read
Small controlled physiology study of growth hormone and short-term food intake.
Small double-blind study showing exposure-related food-intake and hormone effects, not muscle benefit.
Controlled hormone-secretion study in young men; it did not test performance outcomes.
FDA approval & research status
GHRP-2 is not FDA approved. FDA places GHRP-2 for injectable and nasal routes in a compounding category associated with potential significant safety risks.
No FDA-approved use is documented in the records summarized on this page.
No active FDA approval path identified
GHRP-2 has small human physiology studies, but no FDA-approved product and no cited active approval program for muscle, recovery, appetite, or aging uses.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Long-term human safety
- Whether any meaningful muscle, strength, recovery, sleep, or body-composition benefit exists
- Risks of combinations with other growth-hormone-pathway substances
- Product identity and quality outside an approved drug application
The takeaway
GHRP-2 reliably illustrates a common research trap: showing that a peptide changes a hormone does not show that it builds useful muscle or improves performance safely.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2pubmedGHRP-2 food-intake study in healthy men
Small controlled physiology study of growth hormone and short-term food intake.
- 3pubmedRandomized GHRP-2 appetite study
Small double-blind study showing exposure-related food-intake and hormone effects, not muscle benefit.
- 4pubmedRandomized GHRP-2 endocrine physiology study
Controlled hormone-secretion study in young men; it did not test performance outcomes.